Mulligan, G., Lichter, D. I., Di Bacco, A., Blakemore, S. J., Berger, A., Koenig, E., . . . Schu, M. (2014). Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. American Society of Hematology.
Citação norma ChicagoMulligan, George, et al. Mutation of NRAS but Not KRAS Significantly Reduces Myeloma Sensitivity to Single-agent Bortezomib Therapy. American Society of Hematology, 2014.
MLA CitationMulligan, George, et al. Mutation of NRAS but Not KRAS Significantly Reduces Myeloma Sensitivity to Single-agent Bortezomib Therapy. American Society of Hematology, 2014.
Advarsel: Disse citationer er muligvist ikke 100% nøjagtige.